You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

R-CHOP chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Diffuse Large B Cell Lymphoma Trial in Busan (PrednisoLONE 50 MG)

Completed
  • Diffuse Large B Cell Lymphoma
  • PrednisoLONE 50 MG
  • Busan, Sue-gu, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Mantle Cell Lymphoma Trial in Canada (Acalabrutinib, R-CHOP chemo)

Recruiting
  • Mantle Cell Lymphoma
  • Vancouver, British Columbia, Canada
  • +3 more
Mar 17, 2022

Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Dec 1, 2022

Multidisciplinary Care Program to Secure mEdication Therapy for

Not yet recruiting
  • Chemotherapy Effect
  • +2 more
  • Assessment of patient satisfaction regarding tele-consultation
  • +4 more
  • Pierre-Bénite, France
    Hôpital Lyon Sud - Hospices Civils de lyon
Apr 22, 2022

Follicular Lymphoma (FL) Trial (biological, drug, other)

Not yet recruiting
  • Follicular Lymphoma (FL)
  • Tisagenlecleucel
  • +4 more
  • (no location specified)
May 24, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Measure of the circulating tumor DNA
  • Rouen, France
    Centre Henri Becquerel
Nov 17, 2023

Lymphoma, Large B-Cell, Diffuse Trial in Austria, Germany (Glofitamab, Rituximab, Obinutuzumab)

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Linz, Austria
  • +17 more
Mar 22, 2023

Diffuse Large B-cell Lymphoma, HIV Trial in Lilongwe (R-CHOP)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • HIV
  • Lilongwe, Malawi
    UNC Project, Lighthouse Trust
Oct 18, 2021

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,

Recruiting
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +4 more
  • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
  • R-CHOP; R-DA-EPOCH; R-HD MTX
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital
Dec 7, 2021

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified,

Recruiting
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
  • +4 more
  • Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
  • Jinan, Shandong, China
    Shandong Provincial Hospital
Nov 18, 2021

Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Dec 12, 2022

Mantle Cell Lymphoma Trial in United States (R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.)

Active, not recruiting
  • Mantle Cell Lymphoma
  • R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
  • Basking Ridge, New Jersey
  • +4 more
Dec 1, 2022

Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

Active, not recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Ballarat, Victoria, Australia
  • +2 more
Jan 30, 2023

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Orelabrutinib + R-CHOP
  • Placebo + R-CHOP
  • Shanghai, Shanghai, China
    Shanghai Ruijing Hospital
Nov 28, 2022

Follicular Lymphoma Trial in Italy (Immunochemo regimen: Rituximab-bendamustine (Arm A), Immunochemo regimen:

Recruiting
  • Follicular Lymphoma
  • Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)
  • +9 more
  • Barletta, Barletta Andria Trani, Italy
  • +68 more
Oct 13, 2022

Mantle Cell Lymphoma, Untreated Trial in United States (Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC))

Active, not recruiting
  • Mantle Cell Lymphoma
  • Untreated
  • Basking Ridge, New Jersey
  • +6 more
Feb 17, 2022

The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)

Recruiting
  • The First Affiliated Hospital of Nanchang University
  • Nanchang, Jiangxi, China
  • +1 more
Jul 3, 2023

Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
Oct 26, 2022

Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Shenyang, Liaoning, China
    Xing Xiaojing
Jun 1, 2023

Diffuse Large B Cell Lymphoma Trial in Colchester, Canterbury, Nottingham (R-CHOP, R-CHOP + acalabrutinib)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Colchester, Essex, United Kingdom
  • +32 more
Oct 25, 2022

Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma

Completed
  • Lymphoma, Large B-cell, Diffuse
    • Jeonju, Korea, Republic of
      Chonbuk National University Hospital
    Feb 2, 2023

    DLBCL Trial (Sintilimab, Rituximab)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • (no location specified)
    Mar 6, 2022